Researchers at the University of Chicago have identified zeaxanthin, a carotenoid primarily recognized for its role in eye health, as a potent enhancer of CD8+ T cell function in cancer immunotherapy. Published in Cell Reports Medicine, the study reveals that zeaxanthin stabilizes the T-cell receptor complex, amplifying T cell activation and cytokine production, which are critical for effective anti-tumor responses. This finding positions zeaxanthin as a promising adjunct to existing cancer treatments, particularly immunotherapies.

The implications of this discovery are significant. In preclinical models, dietary zeaxanthin not only slowed tumor growth but also improved the efficacy of immune checkpoint inhibitors, a class of immunotherapy that has revolutionized cancer treatment. The combination of zeaxanthin with these therapies yielded stronger anti-tumor responses than immunotherapy alone. Furthermore, laboratory tests on engineered human T cells targeting specific cancer markers showed enhanced destruction of melanoma, multiple myeloma, and glioblastoma cells when zeaxanthin was included.

This research underscores the potential of nutritional immunology, suggesting that dietary components can interact with immune mechanisms at the molecular level to improve cancer treatment outcomes. The accessibility and safety of zeaxanthin, found in common foods like spinach and orange peppers, could facilitate rapid clinical testing as a complementary therapy in oncology. As the field moves forward, these findings may catalyze a shift in how dietary interventions are integrated into cancer care, potentially accelerating drug development timelines and enhancing therapeutic strategies.

Source: sciencedaily.com